Edwards Lifesciences upgraded by Piper Sandler with a new price target
$EW
Industrial Specialties
Health Care
Piper Sandler upgraded Edwards Lifesciences from Neutral to Overweight and set a new price target of $80.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/29/2025 | $100.00 | Neutral → Buy | BTIG Research |
| 4/24/2025 | $80.00 | Neutral → Overweight | Piper Sandler |
| 1/30/2025 | $75.00 → $90.00 | Hold → Buy | Stifel |
| 1/16/2025 | $60.00 | Peer Perform → Underperform | Wolfe Research |
| 12/16/2024 | Neutral → Buy | BofA Securities | |
| 10/11/2024 | $70.00 | Equal-Weight | Morgan Stanley |
| 9/18/2024 | $85.00 → $70.00 | Buy → Hold | Jefferies |
| 7/31/2024 | Neutral → Outperform | Daiwa Securities |
Edwards Lifesciences (NYSE:EW) announced today that the U.S. Federal Trade Commission (FTC) moved to block the company's proposed acquisition of JenaValve Technology. Edwards disagrees with FTC's decision and believes it will limit the availability of an important treatment option for patients suffering from aortic regurgitation (AR). The company further believes the acquisition of JenaValve will accelerate the availability, adoption and continued innovation of a life-saving treatment for patients suffering from AR. AR is a deadly and progressive disease that affects a significant and growing number of patients, many of whom currently have limited treatment options. Edwards intends to
Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended June 30, 2025. Recent Highlights Q2 sales grew 11.9% to $1.53 billion, or 10.6% adjusted1, with strength across all product groups Q2 TAVR sales grew 8.9%; constant currency1 sales grew 7.8% Q2 TMTT sales reached $134.5 million or $133.0 million adjusted1, driven by PASCAL and EVOQUE Q2 EPS of $0.572; adjusted1 EPS of $0.67 SAPIEN platform is only TAVR approved for asymptomatic patients in U.S. and now in Europe EuroPCR data confirm clinical and economic advantages of timely treatment for severe AS patients 10-year data from PARTNER II study confirm long-term outcomes and durability
Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended June 30, 2025 after the market closes on Thursday July 24, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and
SCHEDULE 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)
S-8 - Edwards Lifesciences Corp (0001099800) (Filer)
S-8 - Edwards Lifesciences Corp (0001099800) (Filer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
BTIG Research upgraded Edwards Lifesciences from Neutral to Buy and set a new price target of $100.00
Piper Sandler upgraded Edwards Lifesciences from Neutral to Overweight and set a new price target of $80.00
Stifel upgraded Edwards Lifesciences from Hold to Buy and set a new price target of $90.00 from $75.00 previously
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended June 30, 2025. Recent Highlights Q2 sales grew 11.9% to $1.53 billion, or 10.6% adjusted1, with strength across all product groups Q2 TAVR sales grew 8.9%; constant currency1 sales grew 7.8% Q2 TMTT sales reached $134.5 million or $133.0 million adjusted1, driven by PASCAL and EVOQUE Q2 EPS of $0.572; adjusted1 EPS of $0.67 SAPIEN platform is only TAVR approved for asymptomatic patients in U.S. and now in Europe EuroPCR data confirm clinical and economic advantages of timely treatment for severe AS patients 10-year data from PARTNER II study confirm long-term outcomes and durability
Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended June 30, 2025 after the market closes on Thursday July 24, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and
Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights Q1 sales grew 6.2% to $1.41 billion, or 7.9% adjusted1 Q1 TAVR sales grew 3.8%; constant currency1 sales grew 5.4%, better than expected Q1 TMTT sales grew 58% to $115 million with meaningful contribution to Edwards' growth Q1 EPS of $0.622; adjusted1 EPS of $0.64 SAPIEN M3 CE Mark approval uniquely positions Edwards with a comprehensive TMTT portfolio NCD finalized for transcatheter tricuspid valve replacement, expanding patient access to EVOQUE Multiple TAVR studies presented at ACC confirm the need for urgent patient referral to Heart Team Data from Hear
SC 13G - Edwards Lifesciences Corp (0001099800) (Subject)
SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)
SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)
Intuitive Ventures today announced the appointment of Terri Burke, former head medtech investments at Epidarex Capital and a seasoned operator, as Senior Partner and Dr. Ross Jaffe, a co-founder of Versant Ventures, as Venture Advisor. Both medtech veterans, they will help support the continued growth of Intuitive Ventures in investing in start-ups reimagining the future of minimally invasive care. With more than two decades of medtech investing and operational leadership experience, Burke will help support the growth of the firm's investment platform. With over $250 million in assets under management, Intuitive Ventures invests in founders tackling large, meaningful problems that positive
IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) today announced that following regular succession planning discussions with the Board of Directors, Edwards' chairman and CEO, Michael A. Mussallem, who recently turned 70, has informed the Board of his decision to retire as CEO in connection with the company's Annual Meeting of Stockholders on May 11, 2023. At the 2023 annual meeting, Mussallem will stand for election as non-executive chairman of Edwards' Board. He will be succeeded as CEO by Bernard Zovighian, currently corporate vice pre
IRVINE, Calif., May 5, 2021 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) today announced updates from its annual meeting, in which Edwards' stockholders voted with the board's recommendations on all proxy proposals: All eight director nominees were elected as directors of the company for a one-year term; Stockholders advised that they approve the compensation of the company's named executive officers; Stockholders have approved the Amendment and Restatement of the company's U.S. and International Employee Stock Purchase Plans; Stockholders have ratified the appoi